Eckert & Ziegler BEBIG has recently installed the latest generation MultiSource® device in the leading private clinic in Bogota, Colombia

    Nachrichtenquelle: GlobeNewswire
     |  28.09.2011, 17:42  |  1150 Aufrufe  |   | 

    September 28, 2011

    Seneffe, Belgium, September 28, 2011,  Eckert & Ziegler BEBIG, a global leader in
    brachytherapy, has recently installed the first MultiSource® HDR (High Dose
    Rate) afterloader of the latest generation in the Centro de Control de Cancer
    LTDA in Bogota, Colombia. The system is the first of its kind worldwide and it
    is already used effectively in the treatment of cancer patients.

    Centro de Control de Cancer is one of leading private medical institutions in
    Colombia and a renowned leader in the implementation of high technology in
    cancer treatment in South America. Opened in 1993, it is run by distinguished
    physicians: Armando Gaitan, Juan Carlos Arbelaez, Felipe Torres, Ricardo
    Cendales, Ivan Bobadilla and medical physicists: Jaider Vasques, Ricardo Español
    and Helbert Cortes. The centre is equipped with the latest technology for
    treating cancer including three linear accelerators and one Co-60 (Cobalt 60)
    machine. The new MultiSource® HDR afterloader complements the existing
    therapeutic line ideally. In addition to the MultiSource®, Centro de Control de
    Cancer is using HDRplusTM3.0, the latest version of Eckert & Ziegler BEBIG´s
    treatment planning system, an intuitive software for precise and efficient HDR
    treatment planning, which provides its users with functions that considerably
    simplify and accelerate their preparation of the treatment plan.

    "We have increased our productivity using the MultiSource® afterloader,
    considering that we have a reliable and fast device, accompanied by an excellent
    technical support and easy-to-use planning software. This has been highly
    appreciated by our physicians and physicists. Plans to implement image-guided
    brachytherapy in gynecological tumors and performing in vivo dosimetry are
    already on their way", said doctor Ricardo Cendales, six weeks after the
    installation of the MultiSource® afterloader in the clinic.

    According to the doctors and physicists from the Centro de Control de Cancer in
    Bogota the innovative medical technology like MultiSource® afterloader
    contributes considerably to the facilitation of the clinical practice:  "This is
    a very good example of the optimal results of a good relationship between the
    equipment developers and the clinical practitioners in order to make
    radiotherapy equipment easier, more precise and user friendly." (Armando Gaitan,

    Centro de Control de Cancer treats every day a large number of patients with
    brachytherapy. The three most common pathologies treated with HDR are
    gynecological, prostate and esophagus cancer. The clinic is dedicated to helping
    patients with limited financial resources. As a part of social policy, a special
    foundation was created to support this disadvantaged group of patients and to
    promote higher education to radiation therapy personnel at all levels.

    The medical experts from Bogota see in the use of the MultiSource® afterloader
    an important step towards the fight against cancer and better quality of life
    for the patients: "The clinical introduction of a precise and safe afterloader
    like MultiSource® in combination with an innovative treatment planning system
    which provides more complex and accurate algorithms to the patients dose
    calculation is a perfect reflection of synergy between science and technology to
    improve patients´ quality of  life"  stated Jaider Vasquez, medical physicist at
    the Centro de Control de Cancer.

    Eckert & Ziegler BEBIG´s MultiSource® device can be used with either an iridium-
    192 or a cobalt-60 source. Both sources are ideally suited to treat
    gynecological, prostate, breast, esophageal and lung cancers, as well as some
    cancers of the head and neck. Centro de Control de Cancer has purchased the
    MultiSource® afterloader with an iridium-192 source.

    "Eckert & Ziegler BEBIG is the only company offering a multiple source HDR
    afterloader. With our proprietary Co-60 MultiSource® device, we offer a cost-
    effective solution in the fight against cancer. We have already installed over
    170 MultiSource® systems worldwide, and more than 20,000 patients were treated
    with our systems in 2010, " commented Eckert & Ziegler BEBIG´s Managing Director
    Dr. Edgar Löffler.

    According to the World Health Organization, cancer rates will continue to rise.
    More than 70 percent of all cancer deaths occur in low and middle income
    countries. One reason for this grim death toll is the high cost of the equipment
    for conventional external beam therapy. Investments for brachytherapy are much
    lower. When used with Co-60, the new MultiSource®HDR afterloader reduces
    operating costs by up to 80 percent compared to an Ir-192 system.

    About Eckert & Ziegler BEBIG

    Contributing to saving lives!

    Eckert & Ziegler BEBIG is a European-based group active in the medical device
    segment of the health care industry.

    Eckert & Ziegler BEBIG´s core business is the treatment of cancer using
    brachytherapy, a special form of radiation therapy.

    Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company
    headquarters are in Belgium, with a production facility in Germany and
    subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG
    has a worldwide network of distributors and agents to support the international
    marketing of its product line.

    The company´s products and equipment are intended for use by oncologists,
    radiologists, urologists, and medical physicists.

    Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed
    on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters:
    EZBG.BR; Bloomberg: EZBG:BB).

    Paul-Emmanuel Goethals
    Investor Relations
    Tel.: +32.64.520.808

    This announcement is distributed by Thomson Reuters on behalf of
    Thomson Reuters clients. The owner of this announcement warrants that:
    (i) the releases contained herein are protected by copyright and
    other applicable laws; and
    (ii) they are solely responsible for the content, accuracy and
    originality of the information contained therein.

    Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE


    Wertpapiere des Artikels:

    Wertpapier: Eckert-Ziegler Bg

    Themen: Iridium

    Schreibe Deinen Kommentar



    Enthaltene Werte

    WertpapierKursZeitPerf. %


    Weitere Nachrichten des Autors


    Diskussionen zu den Werten


    Top Nachrichten aus der Rubrik